TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
COSCIENS Biopharma ( (TSE:CSCI) ) just unveiled an update.
COSCIENS Biopharma Inc. has appointed Anna Biehn as the new Chief Executive Officer, effective May 5, 2025. Biehn brings over 25 years of experience in the consumer products and biosciences industries, having previously served as CFO at NuTek Natural Ingredients. The appointment is seen as a strategic move to position COSCIENS as a global leader in natural-based products for health and wellness, leveraging Biehn’s expertise in commercializing natural ingredients. The outgoing CEO, Gilles Gagnon, will remain as a Strategic Advisor and Director, ensuring a smooth transition and continued growth for the company.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products. The company focuses on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources, which are used in leading skincare products and being developed as potential nutraceuticals and pharmaceuticals. COSCIENS is listed on the Nasdaq Capital Market and the Toronto Stock Exchange.
YTD Price Performance: 4.32%
Average Trading Volume: 24,871
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.1M
Find detailed analytics on CSCI stock on TipRanks’ Stock Analysis page.